LCAHA

LCAHA

L649981-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC 50 s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a. In Vitro LCAHA inhibits HCT116 wt and HCT116 p53 -/- colon cancer cells viability with GI 50 s of 0.87±0.09 and 0.96±0.29μM, respectively, and the LD 50 s of 27.8±3.9 and 26.5±0.1μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCT116 wt and HCT116 p53 -/- colon cancer cells Concentration: 0.01, 0.1, 1, 10, and 100 μM Incubation Time: 6 days Result: The GI 50 s are 0.87±0.09 and 0.96±0.29 μM for HCT116 wt and HCT116 p53 -/- colon cancer cells, respectively. Form:Solid

LCAHA （LCA hydroxyamide）是一种去泛素化酶 USP2a 抑制剂，在 Ub-AMC 分析和 Di-Ub 分析中的 IC 50 s 分别为 9.7 μM 和 3.7μM。LCAHA 通过抑制去泛素化酶 USP2a 来破坏 Cyclin D1 的稳定性并诱导 G0/G1 停滞。

117094-40-3

C24H41NO3

391.59 g/mol

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(NO)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@](C[C@@H](CC4)O)([H])CC3)C

DMSO : 45 mg/mL (114.92 mM; Need ultrasonic)